

Formulary Adherence Checklist for NICE Technology Appraisals About Medicines



East and South East England
Specialist Pharmacy Services

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. **Version 5.0 May 1st 2014.**

All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YYYY)	Time to implement (days)	Notes (e.g. rationale, method of making available)
2014-15							
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)	29/08/2014	Dimethyl fumarate - an option for treating adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), only if they do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis and the manufacturer provides the medicine with the discount agreed in the patient access scheme.		x	27/11/2014	90	Red on Bromley CCG RED-AMBER LIST
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)	31/07/2014	Ipilimumab - an option, within its marketing authorisation, for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.		x	29/10/2014	90	Red on Bromley CCG RED-AMBER LIST
Lubiprostone for treating chronic idiopathic constipation (TA318)	31/07/2014	Lubiprostone - an option for adults with chronic idiopathic constipation in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered.		BB	29/10/2014	90	Amber/Green on Bromley CCG RED-AMBER LIST
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (TA317)	31/07/2014	Prasugrel 10mg - an option, in combination with aspirin, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina, non-ST segment elevation myocardial infarction or ST segment elevation myocardial infarction) having primary or delayed percutaneous coronary intervention.		x	29/10/2014	90	Amber on Bromley CCG RED-AMBER LIST

Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)	31/07/2014	Enzalutamide - an option, within its marketing authorisation, for metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy, only if the manufacturer provides enzalutamide with the discount agreed in the patient access scheme.		x	29/10/2014	90	Red on Bromley CCG RED-AMBER LIST
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)	30/06/2014	Canagliflozin - an option in combination with other treatments for some patients with type 2 diabetes.		D	28/09/2014	90	Amber/Green on Bromley CCG RED-AMBER LIST
Psoriatic arthritis (active) - ustekinumab (TA313)	28/05/2014	Ustekinumab - not recommended alone or with methotrexate for adults when the response to previous non-biological disease-modifying antirheumatic drug therapy has been inadequate.		x	26/08/2014	90	Grey on Bromley CCG RED-AMBER LIST
Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)	28/05/2014	Alemtuzumab - an option for adults with active relapsing-remitting multiple sclerosis.		x	26/08/2014	90	Red on Bromley CCG RED-AMBER LIST
Multiple myeloma - bortezomib (induction therapy) (TA311)	23/04/2014	Bortezomib - an option, in combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.		x	22/07/2014	90	Red on Bromley CCG RED-AMBER LIST
Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310)	23/04/2014	Afatinib - an option for adults with locally advanced or metastatic non-small-cell lung cancer only if they have the EGFR-TK mutation and have not had an EGFR-TK inhibitor previously and the drug is provided at the discount agreed in the patient access scheme.		x	22/07/2014	90	Red on Bromley CCG RED-AMBER LIST
Lung cancer (non small cell, non squamous) - pemetrexed (TA309)	23/04/2014	Pemetrexed - not recommended as maintenance treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer in people whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.		x	22/07/2014	90	Grey on Bromley CCG RED-AMBER LIST
			0	3			
			% "Yes"	% "N/A"	-	Average implement time (days)	
Adherence statistics for 2014-15			0%	100%		90	

KEY

BB
D

Bladder and Bowel
Diabetes